Malignancies in systemic lupus erythematosus

Alexandra Ladouceur, Hiromi Tissera, Ann E. Clarke, Rosalind Ramsey-Goldman, Caroline Gordon, James E. Hansen, Sasha Bernatsky

Research output: Chapter in Book/Report/Conference proceedingChapter


This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers.

Original languageEnglish (US)
Title of host publicationSystemic Lupus Erythematosus
Subtitle of host publicationBasic, Applied and Clinical Aspects
Number of pages7
ISBN (Electronic)9780128145517
ISBN (Print)9780128145524
StatePublished - Jan 1 2020


  • breast cancer
  • cancer incidence
  • cervical cancer
  • endometrial cancer
  • HPV
  • immunosuppressive drugs
  • lung cancer
  • lymphoma
  • malignancy
  • ovarian cancer
  • prostate cancer
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)


Dive into the research topics of 'Malignancies in systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this